Source: Fortune
AstraZeneca will pay $425 million upfront for EsoBiotec and may spend up to $575 million more in development and regulatory milestones, the companies said.
Aller á la Source
Nouvelles connexes
Source: Fortune
AstraZeneca will pay $425 million upfront for EsoBiotec and may spend up to $575 million more in development and regulatory milestones, the companies said.